A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetics of RO5024048. Japanese and Caucasian healthy volunteers will be randomized to receive either single oral doses of RO5024048 or placebo. Follow-up is 7-10 days.
A Multiple Center Randomized, Double-Blind, Single-Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics Following Oral Administration of RO5024048 in Healthy Japanese and Caucasian Subjects
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy male and female adults, 20 to 55 years of age, inclusive
Body mass index (BMI) 18 - 30 kg/m2 inclusive
Non-smoker, or previous smoker who discontinued smoking >/= 6 month prior to study entry
Japanese subjects must be first generation: born in Japan, not having lived outside Japan >5 years, able to trace maternal and paternal Japanese ancestry
Female subjects of childbearing potential and male subjects and their partners of childbearing potential must agree to use two forms of contraception
Agree to abstain from alcohol consumption and from strenuous exercise up to 3 days before dosing and throughout study (including the follow-up visit)
Positive pregnancy test
Males whose female partner is pregnant or trying to become pregnant
Positive urine test for drugs of abuse
Positive for alcohol
Positive result on hepatitis B, hepatitis C, or HIV test
Clinically significant disease or abnormalities in laboratory parameters
Participation in an investigational drug, biologic or device study within 3 months before study drug administration
Donation or loss of any blood over 450 mL within 3 months before study drug administration